Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-LYM-1 antibody

Gerald L Denardo, Sally J. DeNardo, Kathleen R. Lamborn, Desiree S. Goldstein, Norman B. Levy, Jerry P. Lewis, Lois F. O'Grady, Antolin Raventos, Linda A. Kroger, Daniel J. Macey, John P McGahan, Stanley L. Mills, Sui Shen

Research output: Contribution to journalArticlepeer-review

101 Scopus citations

Abstract

Purpose: This trial was conducted to assess the toxicity and efficacy of 131I-Lym-1 in patients with either malignant B-cell non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) using low-dose, fractionated radioimmunotherapy (RIT). Materials and Methods: Thirty adult patients who had advanced B-cell malignancies (25 NHL and 5 CLL) had progressed despite standard therapy; 12 patients entered the trial with Karnofsky performance status (KPS) of equal to or greater than 60. Patients were treated with a series of intravenous doses of 131I-Lym-1 with a goal of reaching a cumulative dose in each patient of at least 300 mCi. All patients were Lym-1 reactive. Clinical responses and immediate toxicity were evaluable in all 30 patients and delayed toxicity in 26. Results: Toxicity to Lym-1 antibody occurred with 28% of the 176 doses and was transient. Human antimouse antibodies (HAMA) were generated in 30% after a mean of 4 doses, but interrupted therapy in only 10% of the patients. Thrombocytopenia was dose- limiting: there were no deaths due to toxicity. Tumor regression occurred in 25 (83%) of the patients and was great enough, and durable enough, in 17 (57%) to qualify them as responders; 13 NHL patients and 4 CLL patients. Advanced disease often interrupted therapy prematurely. However, 18 patients received at least 180 mCi of 131I-Lym-1; 17 (94%) of these responded to the therapy. Conclusion: Although advanced disease often interrupted therapy prematurely, the results from 131I-Lym-1 therapy are clearly promising and warrant additional trials.

Original languageEnglish (US)
Pages (from-to)239-254
Number of pages16
JournalCancer Biotherapy and Radiopharmaceuticals
Volume13
Issue number4
StatePublished - 1998

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Fingerprint

Dive into the research topics of 'Low-dose, fractionated radioimmunotherapy for B-cell malignancies using <sup>131</sup>I-LYM-1 antibody'. Together they form a unique fingerprint.

Cite this